Why not you go into those OTC trade where atleast people know its fraud and still you make lots of money.
Common Stock 12/31/2014 P 300,000 A $ 2.83 11,300,000 I See Footnote (1)
Common Stock 12/31/2014 P 4,800 A $ 2.85 11,304,800 I See Footnote (1)
Common Stock 01/02/2015 P 120,000 A $ 2.94 11,424,800 I See Footnote (1)
Common Stock 01/02/2015 P 97,900 A $ 3.05 11,522,700 I See Footnote (1)
Common Stock 01/02/2015 P 500
Names of Reporting Persons.
Conan Laughlin 10.6% (10.9% as of December 31, 2014)
** Shares reported herein for North Tide Capital, LLC (“North Tide”) represent shares which are beneficially owned by North Tide Capital Master, LP (the “Master Fund”), as reported herein, and shares which are beneficially owned by a managed account (the “Account”). North Tide serves as investment manager to both the Master Fund and the Account. Shares reported herein for Mr. Laughlin represent the above referenced shares beneficially owned by the Master Fund and the Account. Mr. Laughlin serves as the Manager of North Tide. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.
Adam Feuerstein's Biotech Blog - TheStreet
Regulators Want Drug Companies to Be Honest About FDA ... Obese Americans taking Contrave to lose weight cut their risk of having a heart attack, stroke or dying from ... is unknown, according to a review of the inhaled insulin published this week by The Medical Letter.
VVUS getting ready after much of resistance at 3 ...break anytime soon as 1mil shares already short today
DUBLIN, March 16, 2015 /PRNewswire/ --
•Company Focused on Moving Forward with its Growth Strategies and Active Pipeline of Acquisition Targets
Endo International plc (NASDAQ: ENDP) (TSX: ENL) today confirmed that it is withdrawing its cash and stock proposal to acquire Salix Pharmaceuticals, Ltd. Endo is moving forward with its growth strategies and active pipeline of acquisition targets across its three core platforms – U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals and International Pharmaceuticals.
Endo issued the following statement:
"While we are disappointed with this outcome, we have been and will continue to be disciplined in our approach to potential acquisitions. We would like to wish Salix and Valeant continued success as they move forward with their transaction. As a next step, Endo is focusing our attention on other opportunities in our robust deal pipeline and on maximizing our organic growth initiatives including progressing our R&D pipeline. We will continue to drive Endo's growth as a global leader in specialty pharmaceuticals and look forward to creating value for our shareholders while improving patients' lives."